Literature DB >> 23813314

Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence.

Giovanni Sotgiu, Rosella Centis, Lia D'Ambrosio, Antonio Spanevello, Giovanni Battista Migliori.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23813314     DOI： 10.1183/09031936.00191712

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  16 in total

1.  The multidrug-resistant tuberculosis threat: old problems and new solutions.

Authors:  Giovanni Sotgiu; Lia D'Ambrosio; Rosella Centis; Ida Mura; Paolo Castiglia; Antonio Spanevello; Giovanni Battista Migliori
Journal:  J Thorac Dis       Date:  2015-09       Impact factor: 2.895

Review 2.  Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action.

Authors:  Katherine A Sacksteder; Marina Protopopova; Clifton E Barry; Koen Andries; Carol A Nacy
Journal:  Future Microbiol       Date:  2012-07       Impact factor: 3.165

Review 3.  Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review.

Authors:  Lia D'Ambrosio; Rosella Centis; Simon Tiberi; Marina Tadolini; Margareth Dalcolmo; Adrian Rendon; Susanna Esposito; Giovanni Battista Migliori
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

Review 4.  The future for early-stage tuberculosis drug discovery.

Authors:  Edison S Zuniga; Julie Early; Tanya Parish
Journal:  Future Microbiol       Date:  2015       Impact factor: 3.165

5.  The Sterilizing Effect of Intermittent Tedizolid for Pulmonary Tuberculosis.

Authors:  Shashikant Srivastava; Devyani Deshpande; Eric Nuermberger; Pooi S Lee; Kayle Cirrincione; Keertan Dheda; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2018-11-28       Impact factor: 9.079

6.  Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.

Authors:  Payam Nahid; Sundari R Mase; Giovanni Battista Migliori; Giovanni Sotgiu; Graham H Bothamley; Jan L Brozek; Adithya Cattamanchi; J Peter Cegielski; Lisa Chen; Charles L Daley; Tracy L Dalton; Raquel Duarte; Federica Fregonese; C Robert Horsburgh; Faiz Ahmad Khan; Fayez Kheir; Zhiyi Lan; Alfred Lardizabal; Michael Lauzardo; Joan M Mangan; Suzanne M Marks; Lindsay McKenna; Dick Menzies; Carole D Mitnick; Diana M Nilsen; Farah Parvez; Charles A Peloquin; Ann Raftery; H Simon Schaaf; Neha S Shah; Jeffrey R Starke; John W Wilson; Jonathan M Wortham; Terence Chorba; Barbara Seaworth
Journal:  Am J Respir Crit Care Med       Date:  2019-11-15       Impact factor: 21.405

7.  Treatment Outcomes Among Pediatric Patients With Highly Drug-Resistant Tuberculosis: The Role of New and Repurposed Second-Line Tuberculosis Drugs.

Authors:  Tea Madzgharashvili; Argita D Salindri; Matthew J Magee; Nestani Tukvadze; Zaza Avaliani; Henry M Blumberg; Russell R Kempker; Nino Lomtadze
Journal:  J Pediatric Infect Dis Soc       Date:  2021-04-30       Impact factor: 3.164

Review 8.  Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review.

Authors:  Giovanni Sotgiu; Lia D'Ambrosio; Rosella Centis; Simon Tiberi; Susanna Esposito; Simone Dore; Antonio Spanevello; Giovanni Battista Migliori
Journal:  Int J Mol Sci       Date:  2016-03-12       Impact factor: 5.923

Review 9.  New anti-tuberculosis drugs and regimens: 2015 update.

Authors:  Lia D'Ambrosio; Rosella Centis; Giovanni Sotgiu; Emanuele Pontali; Antonio Spanevello; Giovanni Battista Migliori
Journal:  ERJ Open Res       Date:  2015-05-06

10.  TLR1 polymorphisms are significantly associated with the occurrence, presentation and drug-adverse reactions of tuberculosis in Western Chinese adults.

Authors:  Wu Peng; Hao Chen; Zhenzhen Zhao; Xuejiao Hu; Yi Zhou; Yingyu Li; Lian Yang; Xuemei Wang; Jiajia Song; Tangyuheng Liu; Qian Wu; Hao Bai; Xiaojun Lu; Jie Chen; Binwu Ying
Journal:  Oncotarget       Date:  2017-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.